RESEARCH Open Access

Synergistic roles of CBX4 chromo and SIM domains in regulating senescence of primary human osteoarthritic chondrocytes



Yu-Hsiu Chen^{1,2,3}, Xin Zhang^{1,4}, David Attarian⁴ and Virginia Byers Kraus^{1,3,4,5*}

Abstract

Background Cellular senescence is a critical factor contributing to osteoarthritis (OA). Overexpression of chromobox homolog 4 (CBX4) in a mouse system was demonstrated to alleviate post-traumatic osteoarthritis (PTOA) by reducing cellular senescence. Additionally, replicative cellular senescence of WI-38 fibroblasts can be attenuated by CBX4. However, the mechanisms underlying this senomorphic function of CBX4 are not fully understood. In this study, we aimed to investigate the role of CBX4 in cellular senescence in human primary osteoarthritic chondrocytes and to identify the functional domains of CBX4 necessary for its function in modulating senescence.

Methods Chondrocytes, isolated from 6 individuals undergoing total knee replacement for OA, were transduced with wild-type CBX4, mutant CBX4, and control lentiviral constructs. Senescence-related phenotypic outcomes included the following: multiple flow cytometry-measured markers (p16 lNK4A, senescence-associated β-galactosidase [SA-β-gal] activity and dipeptidyl peptidase-4 [DPP4], and proliferation marker EdU), multiplex ELISA-measured markers in chondrocyte culture media (senescence-associated secretory phenotypes [SASPs], including IL-1β, IL-6, IL-8, TNF-α, MMP-1, MMP-3, and MMP-9), and PCR array-evaluated senescence-related genes.

Results Compared with control, CBX4 overexpression in OA chondrocytes decreased DPP4 expression and SASP secretion and increased chondrocyte proliferation confirming CBX4 senomorphic effects on primary human chondrocytes. Point mutations of the chromodomain domain (CDM, involved in chromatin modification) alone were sufficient to partially block the senomorphic activity of CBX4 (p16 lNK44 and DPP4 increased, and EdU decreased) but had minimal effect on SASP secretion. Although having no effect on p16 lNK44, DPP4, and EdU, deletion of two small-ubiquitin-like-modifier-interaction motifs (CBX4 Δ SIMs) led to increased SASP secretion (IL-1 β , TNF- α , IL-8). The combination CBX4 CDM Δ SIMs altered all these measures adversely and to a greater degree than the single domain mutants. Deletion of the C-terminal (CBX4 Δ C-box) involved with transcriptional silencing of polycomb group proteins increased IL-1 β slightly but significantly but altered none of the other senescence outcome measures.

Conclusions CBX4 has a senomorphic effect on human osteoarthritic chondrocytes. CDM is critical for CBX4-mediated regulation of senescence. The SIMs are supportive but not indispensable for CBX4 senomorphic function while the C-box is dispensable.

Keywords CBX4, Cellular senescence, DPP4, Senomorphic, Osteoarthritis

*Correspondence: Virginia Byers Kraus vbk@duke.edu

Full list of author information is available at the end of the article



Introduction

Osteoarthritis (OA) is the most common arthritis in adults; the worldwide prevalence of knee OA among individuals aged 15 or over approximates 16% [1]. The symptoms of OA include joint pain and stiffness, which can lead to decreased mobility and increased mortality [2, 3]. However, no disease-modifying anti-osteoarthritis drugs (DMOADs) are yet approved for the treatment of OA. Cellular senescence has been identified as a factor contributing to OA [4-6]. Cellular senescence is characterized by cell cycle arrest and the elicitation of senescence-associated secretory phenotypes (SASPs), which can impact surrounding cells and tissues [7]. Transplantation of senescent fibroblasts into knee joints of mice resulted in development of radiological and histological OA as well as pain and limited motion [8]. Furthermore, a previous study demonstrated that senescent cells accumulate in the cartilage and synovium in a post-traumatic OA (PTOA) mouse model; eliminating these senescent cells from the joint by a senolytic drug (UBX0101) prevented the development of PTOA in this mouse model [6]. These data support the supposition that suppression and regulation of senescence would have high therapeutic potential in OA.

Recently, CBX4 was shown to mitigate post-traumatic OA (PTOA) upon overexpression in a mouse system by reducing cellular senescence [9]. CBX4 is a polycomb repressive complex-1 (PRC1)-associated protein and a SUMO E3 ligase involved in cell cycle regulation and DNA damage repair [10, 11]. CBX4 contains three major functional domains: a chromodomain (CDM) at the N-terminus, small-ubiquitin-like-modifier (SUMO)interaction motifs (SIMs), and a conserved chromobox (C-Box) at the C-terminus. The CDM is involved in chromatin modification and has been linked to the repression of CDKN2A (p16) expression [12, 13]. SIMs consisting of two motifs, SIM1 and SIM2, are responsible for the SUMO E3 ligase function. They facilitate DNA damage repair through BMI1 recruitment regulation [11, 14]. The C-box contributes to the transcriptional silencing function of polycomb group (PcG) proteins by recruiting other PcG proteins to target genes [10]. CBX4 is a repressor of C-MYC, while deletion of the C-box results in enhanced expression of this proto-oncogene [15]. CBX4 upregulation has previously been shown to correlate with tumor growth and metastasis in breast cancer and hepatocellular cancer [16, 17]. In our previous study, we demonstrated that CBX4 protein expression of WI-38 primary human fibroblasts decreased with serial cell replication in culture [18]. Moreover, in association with reduced CBX4 levels, senescence markers increased, whereas activating CBX4 was associated with a decrease of these markers [18]. These findings suggest that CBX4 regulates replicative senescence in WI-38 cells and functions as a senomorphic and potential anti-senescence target; however, direct mechanisms of its senomorphic effect are lacking.

We hypothesized that CBX4 is a senomorphic with direct effects on chondrocyte senescence. To test our hypothesis, we evaluated the change in senescence phenotype and cell proliferation of primary human OA chondrocytes using several widely used markers including $p16^{INK4A}$, senescence-associated β -galactosidase (SA-β-gal) activity, and EdU (5-ethynyl-2'-deoxyuridine) [19]. Additionally, we included dipeptidyl peptidase-4 (DPP4) that we recently identified as a cell surface marker of chondrocyte senescence in OA [20]. We confirmed the senomorphic effect of CBX4 in OA joint tissue by overexpressing CBX4 in chondrocytes isolated from knee joints of OA patients. In addition, through analyses of full-length wild type (WT) and mutant CBX4 constructs carrying loss of function mutations in one of the three known primary functional domains of CBX4, we identified functional domains contributing to the senomorphic effects of CBX4 in primary chondrocytes.

Materials and methods

Primary chondrocyte isolation and culture

Human knee joint tissues were obtained from OA patients during total knee arthroplasty as surgical waste under IRB approval of Duke Hospital (n=6). Human articular cartilage from the tibial plateau and femoral condyle (both lesioned and non-lesioned) was finely diced and digested in pronase 0.1% (weight and volume, w/v, Roche, 10165921001) for 1 h, followed by 0.17% (w/v) type II collagenase (Sigma, C6885) in chondrocyte culture media for 16-18 h yielding a mean (± standard error of mean, SEM) $5.48 \pm 1.01 \times 10^6$ chondrocytes per gram of human articular cartilage [20]. Chondrocyte media contained DMEM/F-12, GlutaMAX[™] (Thermo Fisher, 10565018) with 10% heat-inactivated fetal bovine serum (HI FBS, Thermo, 10082147), Penicillin-Streptomycin 1x (Thermo, 15140122), and 50 µg/ml L-ascorbic acid (Sigma-Aldrich, A8960). Isolated chondrocytes were seeded at a density of 200,000 cells/well in 24 well plates. The primary chondrocytes were cultured in a monolayer for 5 days in chondrocyte culture media and transduced with empty vector control, WT CBX4, or the mutant CBX4 in lentiviral constructs.

Lentiviral particle preparation

Lentiviral particles used for transduction were prepared by VectorBuilder (Chicago, Illinois) (Table 1). mCherry expressing lentiviral particles were used as a control to monitor and optimize transduction efficiency. Wildtype CBX4 cDNA (NM_003655.3) and mutants were cloned

			,	•	
Created vector	Vector ID	Vector name	Size	Function of domain	
Wild-type CBX4 (CBX4 WT)	VB-210801-1043rpz	pLV[Exp]-Puro- CMV > hCBX4[NM_003655.3]	9588 bp		
CDM-mutated CBX4 (CBX4 CDM)	VB-210709-1084wpn	pLV[Exp]-Puro-CMV > hCBX4*(F11A, W35L)	9588 bp	PRC1-related chromatin modification	
SIM-deleted CBX4 (CBX4 ΔSIMs)	VB-210709-1077tkm	pLV[Exp]-Puro-CMV > hCBX4*(delete 262–265, 462-465aa)	9564 bp	SUMO E3 ligase function	
C-box-deleted CBX4 (CBX4 ΔC-box)	VB-210709-1085knf	pLV[Exp]-Puro-CMV > hCBX4*(delete 531-556aa)	9510 bp	Transcriptional silencing function of pcG proteins	
CDM-mutated and SIM-deleted CBX4 (CBX4 CDM Δ SIM)	VB-210709-1088mgj	pLV[Exp]-Puro-CMV > hCBX4* (F11A, W35L; delete 252–265,462-465aa)	9564 bp		
Control (Ctrl)	VB-210808-1067mmj	pLV[Exp]-Puro-CMV	7899 bp		
mCherry control	VB010000-9298rtf	pLV[Exp]-EGFP:T2A:Puro- EF1A > mCherry	10085 bp		

Table 1 CBX4-related lentiviral constructs used for viral transduction of primary human chondrocytes

into pLV-Puro-CMV with lentivirus packaging; pLV-Puro-CMV with lentivirus packaging was used as a control. CDM-mutated CBX4 (CBX4 CDM) was created with F11A and W35L mutants [12]. SIM-deleted CBX4 (CBX4 Δ SIMs) was created with both SIM1 (amino acids 262–265) and SIM2 (amino acids 462–465) deletion [10]. C-box-deleted CBX4 (CBX4 Δ C-box) was created with C-box (amino acids 531–556) deletion [21]. A combination CDM and SIM mutant was also created (CBX4 CDM Δ SIM).

Transduction of lentiviral particles

The addition of mCherry control lentiviral articles at a multiplicity of infection (MOI) of 20, along with spinfection [22] at 900×g for 1 h, resulted in approximately 60% mCherry expression in primary chondrocytes by 3 days after transduction (data not shown). Based on the mCherry control result, we estimated a 60-70% transduction efficiency by CBX4 WT, CBX4 mutant, and control lentiviral constructs in chondrocytes. To mitigate the risk of viral toxicity linked to higher MOI, and avoid inducing senescence through polybrene-related cellular stress [18, 23], we chose not to increase the MOI beyond the selected level and to avoid employing polybrene. CBX4 WT, CBX4-mutated, and control lentiviral constructs were added to primary chondrocytes using spinfection 900×g for 1 h with MOI 20. After transduction, the chondrocytes were cultured for 5 days. The culture media were replaced 24 h after transduction, and then again 4 days later. After the second media replacement, the culture media were collected for a period of 24 h. Subsequently, EdU (Thermo Fisher, C10424) was added to the chondrocyte culture media at a concentration of 10 μM. After 24 h of incubation with EdU, the cells were collected for further analysis.

Flow-cytometric analysis of senescence markers

Chondrocytes were assessed for cellular senescence status by quantification of DPP4 and p16^{INK4A} protein expression, and SA-β-gal activity using flow cytometry as we previously described [18, 20]. For quantification of cell surface DPP4, $1-2\times10^4$ cells were stained with anti-DPP4 monoclonal antibody (2A6), PE (Thermo Fisher, 12-0269-42; 2 µl/100 µl) in phosphate-buffered saline (PBS, Thermo, 10010023) with 1% bovine serum albumin (BSA, Sigma A3294) for 30 min at room temperature, and then washed twice with 600 µl PBS with 1% BSA. Co-staining of SA-β-gal activity with the cell proliferation marker EdU), and senescence marker p16^{INK4A}, was performed as we previously described [18]. Briefly, after cell fixation with 4% paraformaldehyde (PFA, Thermo Fisher 50980487), SA-β-gal activity was quantified using the CellEvent Senescence Green flow cytometry assay (Thermo Fisher, C10840) carried out at 37 °C for 2 h per the manufacturer's instructions. The cells were then permeabilized with permeabilization buffer (Thermo Fisher, 00-8333-56) and stained for p16^{INK4A} or EdU. Anti-p16 mAb (20:100, Roche CINtec kit 9517) was used for p16^{INK4A} staining for 30 min followed by washing and 30 min incubation with AF647conjugated anti-mouse IgG2a secondary antibody (1:1000, Jackson, 115607186). The Click-iT $^{\text{TM}}$ EdU Alexa Fluor[™] 647 flow cytometry assay (Thermo Fisher, C10424) was used to identify EdU positive cells following the manufacturer's instructions. The unstained and stained cells were analyzed using an Attune NxT flow cytometer (Thermo Fisher). Unstained cells were used to determine the fluorescence background. Data were analyzed using the FlowJo V10.8 software (BD Life Sciences).

Western blot

Western blot was performed as previously described [18]. Primary chondrocyte cell lysis and protein extraction were achieved with the PARISTM kit (Thermo Fisher AM1921) with proteinase inhibitors (Sigma-Aldrich, P8340). A total 5 µg of protein lysates was mixed with 4×Laemmli sample buffer (Bio-Rad 1610747) and heated to 95 °C for 5 min. Cell lysates (5 µg/well, Bio-Rad#4568033) were separated on a 10% Mini-PROTEAN® TGX Stain-Free™ protein gels (Bio-Rad, 4568033). Proteins were transferred to polyvinylidene fluoride (PVDF) membranes using the Trans-blot turbo system (Bio-Rad,#1704274). The membrane was blocked with 5% w/v fat-free milk (CST 9999 s) for 1 h at room temperature. Membranes were washed three times with Tris-buffered saline Tween 20 buffer (TBST, Thermo Fisher, 28360) then incubated with the primary antibody, anti-CBX4 mAb (Cell Signaling Technology #30559, 1:1000), or internal control, anti-β-actin mAb-HRP (Santa Cruz Bio, sc-47778 HRP, 1:2000), in TBST containing 5% BSA at 4° C overnight. According to the manufacturer, the anti-CBX4 mAb (Cell Signaling Technology #30559) is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro166 of human CBX4 protein, which should be able to detect all the CBX4 mutants generated. The following day, membranes were washed three times with TBST and incubated with anti-rabbit IgG-HRP (1:500, Thermo Fisher 32460) at room temperature for 1 h. β -actin protein bands were visualized using Clarity[™] Western ECL Substrate (Bio-Rad, 1705060); CBX4 protein bands were visualized using SuperSignal[™] West Pico PLUS Chemiluminescent Substrate (Thermo Fisher 34579). Membrane Images were acquired with the ChemiDoc XRS system (Bio-Rad, USA). Grey band density values were quantified using Image lab (version 6.0, Bio-Rad).

Senescence-associated secretory phenotypes

IL-1β, IL-6, IL-8, and TNF- α were quantified by a V-PLEX Human Proinflammatory Panel II 4-Plex immunoassay (MSD, K15053D) with intra- and inter-assay coefficients of variation (CVs) 3.8%, 4.0%, 3.1%, 2.8% and 6.4%, 6.4%, 6.4%, and 8.0%, respectively. Matrix metalloproteinase (MMP)-1, MMP-3, and MMP-9 were quantified by a Human MMP 3-Plex Ultra-Sensitive Kit (MSD, K15034C) with intra-assay CVs 4.0%, 3.4% and 2.3%, respectively, and inter-assay CVs \leq 18%.

Quantitative real-time polymerase chain reaction (qRT-PCR) and qRT-PCR array

RNA was isolated from transduced primary chondrocytes using a PARIS[™] Kit (Thermo Fisher AM1921). cDNA was

synthesized using the iScript[™] cDNA Synthesis Kit (Bio-Rad, 1708891). Subsequently, qRT-PCR was performed using an SYBR green master mix (Applied Biosystems, 4309155) with a QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). Gene expression of CBX4 was measured using YWHAZ as an internal reference control gene. Primer sequences were as follows: CBX4 Forward ACCGTGCCAAGCTGGATTT; CBX4 Reverse AGG TCGTACATTTTGGGGTCG; YWHAZ Forward CTG AGGTTGCAGCTGGTGATGACA; YWHAZ Reverse AGCAGGCTTTCTCAGGGGGAGTTCA.

A custom RT2 Profiler PCR Array (Qiagen, 330171) was employed to analyze the expression levels of 42 specific genes associated with cellular senescence and/or CBX4 as previously described (Table S1) [18]. The RT² First Strand Kit (Qiagen, 330404) was utilized to synthesize cDNA. Subsequently, qRT-PCR was performed using a RT² SYBR Green ROX qPCR Mastermix (Qiagen, 330522) with the OuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) according to the manufacturer's instructions. The CT value of each gene was normalized with reference gene YWHAZ, $\Delta CT = CT_{target}$ gene - CT_{YWHAZ}. The relative gene expression was calculated by $\Delta\Delta$ CT (Δ CT $_{CBX4~mutant}$ – Δ CT $_{CBX4~WT}$), which was used to calculate the relative expression ratio $(2^{-\Delta\Delta CT})$. Genes with over 40% of values undetected (CT>40) were excluded; for any sample with a gene CT value undetected, CT 40 was imputed. DAO, TP63, LY6D, and SOX2 were not detected; CBX4 was included in the PCR array, but the primer used was not able to detect all the mutants. For these reasons, we excluded these five genes from analysis resulting in a total 37 genes analyzed.

Statistical analysis

Data are presented as mean ± SEM. Analyses were performed using Prism 9 (GraphPad software). Flow cytometry measurements and SASP secretion by primary chondrocytes transduced by either CBX4 WT or control passed the lognormal Shapiro-Wilk and Kolmogorov-Smirnov distribution tests. Following this assessment, ratio-paired t-tests were conducted to further analyze the data. Repeated measures with Dunnett's post hoc test were performed for comparison of WT CBX4 with each of the mutants transduced into chondrocytes; the data for p16^{INK4A}, EdU, IL-1β, and TNF-α exhibited violations of sphericity, necessitating use of a Geisser-Greenhouse correction when calculating the P-values for repeated measures ANOVA. P < 0.05 was considered statistically significant. Benjamini and Hochberg false discovery rate (FDR) < 0.1 and a log2 fold change (FC) > 0.58 thresholds were applied to the qRT-PCR array data analysis.

Results

CBX4 overexpression in primary OA chondrocytes decreased senescence and inflammatory response and increased cell proliferation in primary OA chondrocytes

To investigate the impact of CBX4 on primary chondrocyte senescence status, we successfully and dramatically overexpressed CBX4 gene and protein expression with CBX4 WT transduction. Compared with control lentiviral construct transduced chondrocytes, the mean gene expression (ΔCT) of CBX4 in primary transduced chondrocytes from CBX4 WT was 159-fold higher (P < 0.0001). Similarly, an intense band corresponding to CBX4 protein was identified from the lysate of CBX4 WT-transduced chondrocytes, while no band was detected from the control (vector transduction) cell lysate using the same blot exposure time (3 s). With longer exposure time (40 s), native CBX4 protein expression was detected in chondrocytes transduced with the control lentiviral construct; native CBX4 amount corresponded to levels we observe in comparable amounts of a protein lysate derived from WI-38 senescent cells (data not shown) (Fig. 1A).


Compared with control cells, CBX4 WT-transduced chondrocytes had a significantly lower mean frequency

of DPP4⁺ and p16^{INK4A+} cells and a significant (>threefold) increase in mean cell proliferation based on the EdU⁺ signal (Fig. 1B). CBX4 WT-transduced chondrocytes secreted significantly less mean IL-8, IL-1 β , and TNF- α (Fig. 1C). These findings suggest that CBX4 WT transduction resulted in a senomorphic effect characterized by lower expression of senescence markers, including SASP secretion.

Changes in senescence chondrocyte phenotype in response to CBX4 wild-type and mutants

In human primary OA chondrocytes, we successfully overexpressed CBX4 WT and CBX4 mutants with mutations of the individual major functional domains of CBX4. The mean gene expression (Δ CT) and protein expression of CBX4 from CBX4 WT and all tested CBX4 mutants (CBX4 CDM, CBX4 Δ SIMs, CBX4 Δ C-box, and CBX4 CDM Δ SIMs) were dramatically higher than control (Fig. 2A, B). Additionally, compared with CBX4 WT transduction, CBX4 Δ C-box had lower CBX4 gene expression (Fig. 2A), while CBX4 CDM had higher CBX4 protein expression (Fig. 2B).

Compared with CBX4 WT, despite the highest-level expression of all the constructs, the CBX4 CDM mutant increased senescence as evidenced by a significantly



C Change in secreted SASPs with chondrocyte transduction by CBX4 WT





Fig. 1 Effects of CBX4 on primary human chondrocytes. CBX4 was overexpressed in human OA chondrocytes using CBX4 WT lentiviral particles. **A** CBX4 gene expression (n=6) and protein expression (representative Western blot) in the CBX4 WT and control lentiviral construct (Ctrl) transduced OA chondrocytes. Upon longer exposure of the Western blot, CBX4 protein expression in control transduced primary chondrocytes was comparable to levels of expression we observe in senescent WI-38 (passage 55) cells (data not shown). CBX4: 75 kDa, β-actin: 42 kDa. **B** SA-β-gal activity, protein expression of p16^{INK4A} and DPP4, and EdU proliferation were detected using flow cytometry. **C** Senescence-associated secretory phenotype (SASP) secretion was measured in the culture supernatants of CBX4 WT and vector only control (Ctrl)-transduced OA chondrocytes. Ratio-paired *t*-tests were performed to compare control and CBX4 WT presented as a dot line graph; P values are listed in the figure






Fig. 2 Mapping effects of CBX4 (wild-type and mutants) on primary human chondrocytes. Expression of senescence markers and cell proliferation of primary human chondrocytes transduced by CBX4 wild-type (WT) or mutants. **A** CBX4 gene expression (n=6) and **B** protein expression by Western blot (representative blot with quantification of n=5 biological replicates in dot plot) in cells transduced by the empty vector Control (Ctrl), CBX4 WT, or its mutants. The expected molecular weights of CBX4 WT, CBX4 CDM, CBX4 Δ SIMs, CBX4 Δ C-box, and CBX4 CDM Δ SIM were 75 kDa, 75 kDa, 74 kDa, and 74 kDa, respectively. **C** Protein-level expression of senescence markers DPP4, SA- β -gal activity, and p16. Protein-level expression of senescence markers DPP4, SA- β -gal activity, and p16. Protein-level as a dot bar graph. Repeated measures with Dunnett's post hoc test were performed to compare the effects of CBX4 WT and mutants. *P \le 0.05, **P \le 0.01, ***P \le 0.001, ****P \le 0.001, ****P \le 0.001


higher mean percentage of chondrocytes expressing senescence-associated biomarkers, DPP4 and p16 $^{\rm INK4A}$, but a significantly lower mean percentage of EdU+ proliferating cells (Fig. 2C). The individual CBX4 $\Delta {\rm SIMs}$ and CBX4 $\Delta {\rm C-box}$ mutants did not affect these senescence outcomes. Compared with CBX4 CDM, the CBX4 CDM $\Delta {\rm SIM}$ combination mutant further increased mean p16 $^{\rm INK4A}$ and further reduced cell proliferation. These data show that CDM is critical for CBX4-mediated regulation of senescence, while the SIMs are supportive but not indispensable for CBX4 senomorphic function (Fig. 2C).

Next, we investigated SASP secretion by OA chondrocytes overexpressing CBX4 WT and CBX4 mutants. Compared with CBX4 WT, chondrocytes transduced with the combination CBX4 CDM Δ SIM mutant secreted significantly more IL-1 β , IL-6, IL-8, TNF- α , and MMP-1 (Fig. 3, n=6). Compared to CBX4 WT, the individual

CBX4 ΔSIM mutant also secreted significantly more IL-1 β , IL-8, and TNF- α . In addition, compared with wild type control, we observed a significant increased IL-1 β secretion by the ΔC -box and marginally increased secretion by the CDM mutation. These SASP findings demonstrate that the CBX4 SIM domains in large part regulate SASP secretion in primary chondrocytes. Thus, the combination CBX4 CDM $\Delta SIMs$ altered all the measures (primary senescence markers and SASPs) adversely and to a greater degree than the single domain mutants demonstrating the synergy of these domains for CBX4 senomorphic functions.

Senescence-related PCR-array analysis in response to CBX4 overexpression

Analysis of expression of a total of 37 selected genes revealed that the most deleterious impact on CBX4 senomorphic capability in primary human OA chondrocytes



was observed with the CBX4 CDMΔSIM mutant, i.e., the combination of CDM and SIM mutations: increased apoptosis inducer FAS (P=0.03), increased senescence gene CDKN2A (P=0.003), increased inflammatory chemokine CXCL8 (P=0.02), and marginally increased SASP, TNF (P=0.09), and decreased cell proliferation-related gene PCNA (P=0.02) (Fig. 4). In addition, compared with CBX4WT, CBX4 \(\Delta C\)-box significantly increased HDAC1 (P = 0.006) known to restrict transcription initiation frequency [24] and transcriptional elongation [25]. CBX4 \(\Delta SIMs \) marginally increased \(CXCL8 \) (P=0.07) and decreased expression of the transcriptional repressor, RING1 (P=0.08) (Fig. 4). Based on FDR < 0.1 and log2 FC>0.58, the combination of CDM and SIM mutations of CBX4 significantly increased CDKN2A and CXCL8.

Discussion

In this study, we demonstrated the senomorphic effect of CBX4 overexpression in human OA chondrocytes, based on decreased DPP4 expression, p16^{INK4A} and SASP

secretion, and increased proliferation indicated by the EdU assay. Our findings strongly support a senomorphic role of CBX4 in OA chondrocytes and the potential for exogenous CBX4 as a senomorphic treatment in OA. In addition, we investigated the role of CDM, SIM motifs, and C-box domains of CBX4 in regulating senescence of primary OA chondrocytes. Double point mutations of the CDM domain alone were enough to partially block the senomorphic activity of CBX4. The deletion of SIMs alone enhanced secretion of multiple SASPs, without significantly affecting any of the other assessed parameters indicative of senescence in OA chondrocytes. However, CDM mutations together with deletion of the two SIM domains, the CDM\(Delta\)SIM mutant, synergistically blocked the senomorphic effects of CBX4, as demonstrated by increased senescence-related protein and/or gene expression (DPP4, p16^{INK4A}/CDKN2A, CXCL8), reduced cell proliferation (EdU), and increased SASP secretion (IL-1 β , IL-6, IL-8, TNF- α , and MMP-1). Although the CBX4 ΔC-box significantly decreased IL-1β secretion, deletion of this domain did not significantly impact any




Fig. 4 Senescence-related gene expression profiling of CBX4 wild-type and mutants in primary human OA chondrocytes. The heatmap depicts the relative gene expression by primary human OA chondrocytes transduced with CBX4 wild-type (WT) or four CBX4 mutants of a select group of genes quantified by qPCR array. Gene expression is shown as a log2 ratio of expression level by CBX4 mutant-transduced cells relative to the CBX4 WT-transduced condition. The genes in the heatmap are organized vertically based on their functional properties: green text labels (top *y*-axis) are genes associated with cell proliferation; black text labels (middle *y*-axis) are genes related to DNA damage repair and apoptosis; red text labels (bottom *y*-axis) are genes related to SASPs (senescence-associated secretory phenotypes) and cellular senescence. The most deleterious impact on CBX4 senomorphic capability was caused by the combination of CDM and SIM mutations (far right column). $^{\#}P \le 0.1$ $^{*}P \le 0.05$, $^{**}P \le 0.01$

of the other indicators of OA chondrocyte senescence. Our findings suggest that the CDM domain is essential for CBX4 senomorphic function, while the SIM domains play a secondary or modulatory role with a primary impact on SASP secretion.

We investigated the effect of CBX4 on chondrocyte senescence using several markers, including a newly identified marker, DPP4, whose expression on the surface of OA chondrocytes we showed is associated with higher cellular secretion of SASP factors [20]. Compared with

control, CBX4 overexpression in human OA chondrocytes significantly decreased DPP4 expression, p16^{INK4A} expression, and SASP secretion. These observations are consistent with our prior observations in WI-38 cells in which DPP4 expression and p16INK4A expression were upregulated and downregulated by CBX4 decrease and increase, respectively [18], suggesting that CBX4 may modulate senescence in chondrocytes, in part, through regulation of DPP4 and p16^{INK4A}. The CDM (chromodomain) of CBX4 is known to repress the expression of cyclin-dependent kinase inhibitors, such as p16INK4a and p14/p19^{ARF}, through the action of PRC1 [26, 27]. Previous research has shown that PRC1 binds to the p16 promoter and represses its expression in young cells [28]. It is yet to be determined whether DPP4 is a direct target and/or mediator of CBX4 regulation of senescence.

Although CBX4 overexpression led to significant decreases in p16INK4A and DPP4, it did not result in a notable reduction of SA-β-gal levels. This observation could be a result of the intricate regulation of senescence pathways, with CBX4 potentially influencing some pathways more strongly than others. Other factors, including distinct threshold requirements for detection and heterogeneous cellular responses, could also contribute to this phenomenon. In addition, senescence is a dynamic process that can involve both early and late events. The observed changes might be time-dependent, and the assessment might not have captured the optimal time point for observing changes in SA-β-gal levels. Future investigations, such as employing a stressor-induced model to potentially elevate SA-β-gal activity expression beyond the threshold, or considering different time points and alternative assays, might provide insights into the specific effects of CBX4 on senescence.

The SIM motif is related to the function of SUMO E3 ligase of CBX4. Sumoylation is a post-translational modification process where a member of the SUMO family of proteins is covalently attached to other proteins, thereby modifying their function [29]. A prior study showed that CBX4-mediated SUMO-modification was crucial for DNA damage repair by BMI1 [11]. Moreover, CBX4 can auto-sumoylate C-terminal binding protein, which is responsible for gene repression [30], and facilitate its own function [10]. Sumoylation has recently been found to be involved in senescence regulation, and the sumoylation of different proteins can have varied implications in senescence development [29]. For instance, sumoylation of SIRT1 promotes the survival of normal and cancer cells [31, 32], while sumoylation of protein peroxiredoxin 6 impairs its cell protective function [33]. We speculate that deletion of SIMs of CBX4 may impair DNA damage repair and increase expression of genes involved in senescence regulation. The CBX4 CDMΔSIM showed the greatest deleterious impact on senomorphic outcomes. The SIM deletions were mostly harmful in the context of the CDM mutations. The observed phenomenon can be attributed to the fact that CDM primarily regulates cell cycle checkpoint control. Thus, the mutation of CDM directly leads to cellular senescence. Following cellular senescence, the absence of SIMs further exacerbates the senescence phenotypes. However, SIM deletion is mainly associated with DNA damage repair. In this non-stress model system, the impact of SIM deletion was observed to relate primarily to SASP secretion.

We observed decreased transcript expression in CBX4 Δ C-box compared to CBX4 WT-transduced chondrocytes. The C-box is crucial to the transcriptional silencing role of polycomb group (PcG) proteins, attracting other PcG proteins to target genes. Deletion of the CBX4 C-box can diminish its transcriptional activity, reflecting the intricate functions of PcG proteins; they repress genes through polycomb repression complexes (PRCs) and histone modifications, while also activating transcription via interactions with elements such as transcription factors, non-coding RNAs, and post-translational modifications [34].

There were several limitations of this study. While CBX4 WT transduction exhibited a senomorphic effect in OA chondrocytes, the intrinsic expression levels of endogenous CBX4 in normal tissue relative to OA tissue remain uncertain. Our prior work suggests a modest upregulation of CBX4 in senescent (DPP4⁺) primary human chondrocytes that are enriched in OAlesioned cartilage that is insufficient to fully counteract their senescence phenotype [20]. A comparative analysis between OA and normal cartilage or distinct regions within OA tissue could reveal valuable insights into the role of CBX4 in maintaining cartilage homeostasis and processes related to OA. To identify the effect of CDM, SIM, and C-box in senescence regulation, we tested each domain's function separately. We did not test all combinations of mutants, only CDM mutations in combination with the SIM deletions; a broader combination could further the understanding of the interaction of the functional domains of CBX4. Moreover, the observed impact of various CBX4 mutations may be different under cell stress conditions, particularly for SIMs. We transduced human OA chondrocytes in bulk with CBX4 without antibiotic selection; thus, we evaluated the mean senomorphic outcomes of the total cell population; therefore, these results may underestimate the overall senomorphic effects of CBX4 and the impact of mutating its functional domains that might have been discerned with pre-selection of an at-risk chondrocyte population (e.g., senescent) or specific analysis of the cells that were effectively transduced.

We nevertheless achieved a relatively high transduction efficiency; therefore, we believe these results to be generalizable to the biological effects that CBX4 is likely to have in vivo.

Conclusions

In summary, we showed that CBX4 has a senomorphic effect on human osteoarthritic chondrocytes as evidenced by decreased DPP4, p16^{INK4A}, and SASP secretion and increased cell proliferation. Additionally, we found a predominant effect of the CDM (chromodomain) and synergy with the SIM domains with respect to CBX4 regulation of chondrocyte senescence. CDM is mostly involved in maintaining cell cycle proliferation by decreasing p16^{INK4A} expression. The SIMs are involved in blocking SASP secretion and enhancing DNA damage repair. Taken together, we conclude that CBX4 is a multifunctional protein whose domains play synergistic roles in senescence regulation in human chondrocytes.

Abbreviations

OA Osteoarthritis

CBX4 Chromobox homolog 4 SA-β-gal Senescence-associated β-galactosidase

DPP4 Dipeptidyl peptidase-4

SASPs Senescence-associated secretory phenotypes

CDM Chromodomain

SUMO Small ubiquitin-like modifier SUMO interaction motifs

C-box Chromobox

DMOADs Disease-modifying anti-osteoarthritis drugs

PTOA Post-traumatic osteoarthritis
PRC1 Polycomb repressive complex -1

PcG Polycomb group EdU 5-Ethynyl-2'-deoxyuridine

WT Wild type
w/v Weight/volume

HI FBS Heat-inactivated fetal bovine serum

SEM Standard error of mean CBX4 CDM CDM-mutated CBX4 CBX4 ΔSIMs SIM-deleted CBX4 CBX4 ΔC-box C-box-deleted CBX4

CBX4 CDM SIM A combination CDM and SIM mutant

Ctrl Control
MOI Multiplicity of infection
PFA Paraformaldehyde
CV Coefficients of variation
FDR False discovery rate

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13075-023-03183-8.

Additional file 1: Table S1. qPCR custom microarray panel (Qiagen, 330171). **Supplementary Figure 1.** The Western blot underwent a selective exposure with a cutoff at 70 kDa, reflecting substantial variations in protein expression levels between CBX4 and β-actin. In Fig. 1A, the blot was further tailored to highlight regions specific to the Control (Ctrl) and CBX4 Wild Type (WT) samples; Fig. 2B, focused on CBX4 WT and its

mutants within the molecular weight range of 70-100 kDa for CBX4 and 40-55 kDa for $\beta\text{-actin}.$

Acknowledgements

Not applicable.

Authors' contributions

YHC, XZ, and VBK conceived and designed the experiments. DA provided the TKR samples. YHC performed the experiments. YHC analyzed the data. YHC, XZ, and VBK drafted and revised the manuscript. All authors reviewed, edited, and approved the final version of the manuscript.

Funding

Funded in part by a student grant from government of Taiwan (Y-HC), NIH/NIA P30-AG028716 (VBK) and NIH/NIA R01AG070146 (VBK and XZ).

Availability of data and materials

All data generated or analyzed during this study are included in the published article.

Declarations

Ethics approval and consent to participate

All samples were obtained with IRB approval from Duke University Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Duke Molecular Physiology Institute, Duke University, 300 N Duke St, Durham, NC 27701, USA. ²Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. ³Department of Pathology, Duke University Medical Center, Durham, NC, USA. ⁴Department of Orthopaedic Surgery, Duke University, Durham, NC, USA. ⁵Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Received: 28 July 2023 Accepted: 3 October 2023 Published online: 12 October 2023

References

- Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020;29-30:100587.
- Hawker GA, Croxford R, Bierman AS, Harvey PJ, Ravi B, Stanaitis I, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PloS One. 2014;9(3):e91286-e.
- Haugen IK, Ramachandran VS, Misra D, Neogi T, Niu J, Yang T, et al. Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham heart study. Ann Rheum Dis. 2015;74(1):74–81.
- McCulloch K, Litherland GJ, Rai TS. Cellular senescence in osteoarthritis pathology. Aging Cell. 2017;16(2):210–8.
- Price JS, Waters JG, Darrah C, Pennington C, Edwards DR, Donell ST, et al. The role of chondrocyte senescence in osteoarthritis. Aging Cell. 2002;1(1):57–65.
- Jeon OH, Kim C, Laberge R-M, Demaria M, Rathod S, Vasserot AP, et al. Local clearance of senescent cells attenuates the development of posttraumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23:775.

- González-Gualda E, Baker AG, Fruk L, Muñoz-Espín D. A guide to assessing cellular senescence in vitro and in vivo. FEBS J. 2021;288(1):56–80.
- 8. Xu M, Bradley EW, Weivoda MM, Hwang SM, Pirtskhalava T, Decklever T, et al. Transplanted senescent cells induce an osteoarthritis-like condition in mice. J Gerontol A Biol Sci Med Sci. 2017;72(6):780–5.
- Ren X, Hu B, Song M, Ding Z, Dang Y, Liu Z, et al. Maintenance of nucleolar homeostasis by CBX4 alleviates senescence and osteoarthritis. Cell Rep. 2019;26(13):3643-56.e7.
- Merrill JC, Melhuish TA, Kagey MH, Yang S-H, Sharrocks AD, Wotton D. A role for non-covalent SUMO interaction motifs in Pc2/CBX4 E3 activity. PLoS ONE. 2010;5(1):e8794.
- Ismail IH, Gagné J-P, Caron M-C, McDonald D, Xu Z, Masson J-Y, et al. CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage. Nucleic Acids Res. 2012;40(12):5497–510.
- 12. Luis NM, Morey L, Mejetta S, Pascual G, Janich P, Kuebler B, et al. Regulation of human epidermal stem cell proliferation and senescence requires polycomb-dependent and-independent functions of Cbx4. Cell Stem Cell. 2011;9(3):233–46.
- Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci. 2010;35(6):323–32.
- Li J, Xu Y, Long X-D, Wang W, Jiao H-K, Mei Z, et al. Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer Cell. 2014;25(1):118–31.
- Satijn DP, Olson DJ, van der Vlag J, Hamer KM, Lambrechts C, Masselink H, et al. Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Mol Cell Biol. 1997;17(10):6076–86.
- Zeng JS, Zhang ZD, Pei L, Bai ZZ, Yang Y, Yang H, et al. CBX4 exhibits oncogenic activities in breast cancer via Notch1 signaling. Int J Biochem Cell Biol. 2018;95:1–8.
- 17. Liang Y-K, Lin H-Y, Chen C-F, Zeng D. Prognostic values of distinct CBX family members in breast cancer. Oncotarget. 2017;8(54):92375–87.
- Chen Y-H, Zhang X, Ko K-Y, Hsueh M-F, Kraus VB. CBX4 regulates replicative senescence of WI-38 fibroblasts. Oxid Med Cell Longev. 2022;2022:5503575.
- 19. Jeon OH, David N, Campisi J, Elisseeff JH. Senescent cells and osteoarthritis: a painful connection. J Clin Investig. 2018;128(4):1229–37.
- Chen YH, Zhang X, Chou CH, Hsueh MF, Attarian D, Li YJ, et al. Association of Dipeptidylpeptidase 4 (CD26) With Chondrocyte Senescence and Radiographic Progression in Knee Osteoarthritis. Arthritis Rheumatol. 2023;75(7):1120-31.
- Vincenz C, Kerppola TK. Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences. Proc Natl Acad Sci. 2008;105(43):16572–7.
- Chen CG, Thuillier D, Chin EN, Alliston T. Chondrocyte-intrinsic Smad3 represses Runx2-inducible matrix metalloproteinase 13 expression to maintain articular cartilage and prevent osteoarthritis. Arthritis Rheum. 2012;64(10):3278–89.
- Lin P, Correa D, Lin Y, Caplan Al. Polybrene inhibits human mesenchymal stem cell proliferation during lentiviral transduction. PLoS ONE. 2011;6(8):e23891.
- Gowthaman U, Ivanov M, Schwarz I, Patel HP, Müller NA, García-Pichardo D, et al. The Hda1 histone deacetylase limits divergent non-coding transcription and restricts transcription initiation frequency. EMBO J. 2021;40(23):e108903.
- Ha SD, Ham S, Kim MY, Kim JH, Jang I, Lee BB, et al. Transcription-dependent targeting of Hda1C to hyperactive genes mediates H4-specific deacetylation in yeast. Nat Commun. 2019;10(1):4270.
- van Wijnen AJ, Bagheri L, Badreldin AA, Larson AN, Dudakovic A, Thaler R, et al. Biological functions of chromobox (CBX) proteins in stem cell self-renewal, lineage-commitment, cancer and development. Bone. 2021;143:115659.
- Mardaryev AN, Liu B, Rapisarda V, Poterlowicz K, Malashchuk I, Rudolf J, et al. Cbx4 maintains the epithelial lineage identity and cell proliferation in the developing stratified epithelium. J Cell Biol. 2016;212(1):77–89.
- LaPak KM, Burd CE. The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res. 2014;12(2):167–83.
- Princz A, Tavernarakis N. The role of sumoylation in ageing and senescent decline. Mech Ageing Dev. 2017;162:85–90.

- Li B, Zhou J, Liu P, Hu J, Jin H, Shimono Y, et al. Polycomb protein Cbx4 promotes SUMO modification of de novo DNA methyltransferase Dnmt3a. Biochem J. 2007;405(2):369–78.
- 31. Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol. 2007;9(11):1253–62.
- 32. Campagna M, Herranz D, Garcia MA, Marcos-Villar L, González-Santamaría J, Gallego P, et al. SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ. 2011;18(1):72–9.
- Chhunchha B, Fatma N, Kubo E, Singh DP. Aberrant sumoylation signaling evoked by reactive oxygen species impairs protective function of Prdx6 by destabilization and repression of its transcription. FEBS J. 2014;281(15):3357–81.
- 34. Wang J, Yang B, Zhang X, Liu S, Pan X, Ma C, et al. Chromobox proteins in cancer: multifaceted functions and strategies for modulation (Review). Int J Oncol. 2023;62(3):36.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

